Drug intelligence / Profile preview

Huanghua Fuyantin Granules

Development stage: Unknown
Lead developer: Zhejiang Institute of Traditional Chinese Medicine
Administration: Oral

Overview

Huanghua Fuyantin Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Zhejiang Institute of Traditional Chinese Medicine. It is categorized as a Class 6 TCM new drug and is intended for the oral treatment of pelvic inflammatory disease (PID) and its sequelae. The formulation is based on traditional herbal principles, utilizing a multi-component approach to address inflammatory conditions of the female reproductive system. The drug received clinical trial approval in November 2016 (Approval No. 2016L10229) and entered Phase 1 clinical development. The project is currently positioned for technology transfer by the developing institute.

Other names: 黄花妇炎婷颗粒Huanghua Fuyantin 颗粒

Beyond the preview

Go deeper on Huanghua Fuyantin Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huanghua Fuyantin Granules.

Explore the full profile